Eli Lilly’s LLY gets boost as analysts cite fresh retatrutide trial results and a wider push into next-gen obesity drugs

Eli Lilly and Co. is drawing fresh attention from investors as analysts pointed to new clinical readouts for retatrutide, the company’s next-generation obesity and metabolic drug, and as a separate market list categorized the stock among “best dividend” candidates. In a recent market-linked report, Jefferies raised its price recommendation on Lilly’s shares to $1,350 from $1,330 while reiterating a Buy rating, arguing that the drug’s overall profile in large Phase 3 work will be hard for competitors to match.

Jefferies’ update came as Lilly released full data from two retatrutide studies. The company’s Phase 3 program includes TRIUMPH-1, which enrolled treatment-naive adults with obesity, and TRANSCEND-T2D-1, which studied retatrutide in people with Type 2 diabetes. The report said Lilly presented the complete results at the American Diabetes Association meeting in New Orleans.

According to the cited discussion of the Jefferies view, investors focused on performance tied to retatrutide’s lower 4 mg dose. In the obesity study described in the post, the treatment delivered about 19% weight loss, which was characterized as comparable to results seen with Lilly’s higher-dose benchmark obesity therapy, Zepbound. The same update also described tolerability as broadly consistent with expectations, including relatively low levels of vomiting and similar rates of treatment discontinuation.

The post also noted that while some safety observations were present, Jefferies believed they were manageable. It added that the firm expects retatrutide’s overall profile to be difficult to beat in a modern, large-scale global obesity Phase 3 trial. In other words, the bullish framing was less about a single headline number and more about the perceived durability of benefit versus side-effect risk as Lilly moves from study readouts toward broader Phase 3 deployment.

Separately, the “10 Best Dividend Stocks to Buy According to D. E. Shaw” angle appears to be a reference to Lilly’s inclusion in a dividend-focused screen attributed to D. E. Shaw. D. E. Shaw is described in the same reporting as building parts of its investment approach around quantitative methods, later expanding into other strategies. The dividend list itself did not, in the account used here, lay out a detailed methodology or specific dividend yield figures for Lilly, so investors looking for that level of detail would need to consult the underlying list directly.

For Lilly, the retatrutide narrative matters because it sits in the company’s central growth strategy: expanding the weight-loss and diabetes franchise beyond Zepbound and into an upgraded class that targets multiple metabolic pathways. Retatrutide is being positioned to strengthen Lilly’s competitiveness in a market where rivals are also racing to improve efficacy, dosing convenience, and tolerability across broader patient populations.

Still, several items remain unclear from the reporting used for this story. Neither the market-linked post nor the dividend-focused framing provides full trial tables, longer-term endpoints such as durability of weight loss over extended periods, or a granular breakdown of adverse events at each dose level. Investors will likely want to track how Lilly and partner researchers summarize safety findings across subgroups and whether the benefits hold in broader real-world-like populations as Phase 3 trials progress.

Next, attention should center on how Jefferies and other analysts translate the Phase 3 obesity and Type 2 diabetes data into updated forecasts for timelines, market uptake, and margin implications. For shareholders, the near-term watch list includes additional Phase 3 milestones and any further regulatory or submission-related steps that Lilly may take after full data presentations. The dividend-screen angle, meanwhile, is likely to keep the stock in broader retail and income-focused crosshairs even as the company’s growth case remains tied to obesity drug efficacy and tolerability.